18.70
+0.38%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue, before interest expense
$97.8m
FY2016FY2025
Net income
$7.1m
FY2016FY2025
Total assets
$162.3m
FY2016FY2025
Shareholders' equity
$125.6m
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue, before interest expense | $97.8m | $94.7m | $89.8m | $68.7m | $73.1m | $65.1m | $84.1m | $122.3m | $133.8m | $123.0m |
| Research and development | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $6.9m | $830,000 | $6.0m | −$4.9m | $6.0m | −$3.4m | $4.6m | $35.9m | $33.9m | $34.0m |
| Net income | $7.1m | $2.2m | $10.6m | −$4.6m | $9.8m | −$8.9m | $5.9m | $26.8m | $20.0m | $22.6m |
| Diluted earnings per share | 0.79 | 0.26 | 1.29 | -0.60 | 1.23 | -1.14 | 0.70 | 3.15 | 2.34 | 2.74 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $162.3m | $150.0m | $155.2m | $146.4m | $139.6m | $149.2m | $178.7m | $199.2m | $192.7m | $179.7m |
| Cash and short-term investments | $47.7m | $46.5m | $53.1m | $39.2m | $80.2m | $82.6m | $100.1m | $118.2m | $105.6m | $90.2m |
| Total liabilities | $35.6m | $27.7m | $32.7m | $35.8m | $21.7m | $18.4m | $30.4m | $38.0m | $36.3m | $33.6m |
| Debt | $10.2m | — | — | — | — | — | — | — | — | — |
| Shareholders' equity | $125.6m | $120.3m | $120.4m | $110.6m | $117.9m | $130.7m | $148.3m | $161.1m | $156.4m | $146.1m |
| Shares outstanding | 9m | 9m | 8m | 8m | 8m | 8m | 8m | 9m | 9m | 8m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue, before interest expense | $25.3m | $25.0m | $27.1m | $24.3m | $23.1m | $23.3m | $25.6m | $23.7m |
| Operating income | $2.1m | −$1.5m | $4.1m | $2.0m | $868,000 | −$68,000 | $2.6m | −$494,000 |
| Net income | $1.5m | $782,000 | $1.9m | $3.7m | $1.0m | $477,000 | $2.1m | $159,000 |
| Diluted earnings per share | 0.17 | 0.09 | 0.21 | 0.41 | 0.11 | 0.05 | 0.24 | 0.02 |
| Total assets | $155.4m | $150.4m | $163.3m | $154.0m | $146.3m | $135.0m | $150.0m | $151.5m |
| Cash and short-term investments | $22.6m | $23.4m | $47.7m | $39.3m | $33.2m | $27.0m | $46.5m | $48.3m |
| Debt | $12.4m | $10.0m | $10.2m | $10.3m | $10.5m | $2.9m | $3.2m | $1.5m |
| Shareholders' equity | $126.3m | $125.0m | $125.6m | $123.9m | $120.3m | $119.3m | $120.3m | $118.4m |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 12.5% | 8.5% | -2.9% |
| Operating income | — | — | -16.6% |
| Net income | — | — | -12.6% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Operating margin | 4.0% | 2.5% | 2.3% | 15.0% |
| Net margin | 4.8% | 4.3% | 3.3% | 10.9% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 21.9 | 55.9 | 9.7 | -18.7 | 13.7 | -11.5 | 38.4 | 9.8 | 25.7 | 19.9 |
| Price to sales | 1.6 | 1.3 | 1.1 | 1.3 | 1.8 | 1.6 | 2.7 | 2.1 | 3.8 | 3.6 |
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | 23% | 25% | 18% | -40% | 45% | -59% | -8% | -48% | 5% | 23% |
Dividends and splits
Per share, in the currency the company pays
Paid for 24 years. Last went ex-dividend on 3 Mar 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.15 | 0.60 | 0.60 | 0.60 | 0.60 | 2.95 | 0.43 | 2.88 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.